October 24, 2022
3 min watch
Save
VIDEO: Gene therapy shows positive safety, tolerability results for geographic atrophy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
CHICAGO — In this Healio Video Perspective from the AAO meeting, Michael Nathan Cohen, MD, discusses phase 1 data investigating JNJ-81201887 gene therapy from Janssen for the treatment of geographic atrophy.
According to Cohen, JNJ-81201887 met its primary safety and tolerability endpoints in all doses evaluated. The only notable adverse event was mild inflammation in 29% of patients.
Published by:
Sources/Disclosures
Collapse
Source:
Cohen MN. Phase 1 study of JNJ-81201887 gene therapy in geographic atrophy (GA) due to age-related macular degeneration (AMD). Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.
Disclosures:
Cohen reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.